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Background: Previous randomized studies have demonstrated that fesoterodine significantly improves the
Overactive Bladder (OAB) symptoms and their assessment by patients compared with tolterodine extended-release
(ER). This study aimed to assess the effect of aging and dose escalation on patient-reported treatment benefit, after
changing their first Overactive Bladder (OAB) therapy with tolterodine-ER to fesoterodine in daily clinical practice.
Methods: A post-hoc analysis of data from a retrospective, cross-sectional and observational study was performed
in a cohort of 748 OAB adults patients (OAB-V8 score ≥8), who switched to fesoterodine from their first
tolterodine-ER-based therapy within the 3–4 months before study visit. Effect of fesoterodine doses (4 mg vs. 8 mg)
and patient age (<65 yr vs. ≥65 yr) were assessed. Patient reported treatment benefit [Treatment Benefit Scale
(TBS)] and physician assessment of improvement with change [Clinical Global Impression of Improvement subscale
(CGI-I)] were recorded. Treatment satisfaction, degree of worry, bother and interference with daily living activities
due to urinary symptoms were also assessed.
Results: Improvements were not affected by age. Fesoterodine 8 mg vs. 4 mg provides significant improvements
in terms of treatment benefit [TBS 97.1% vs. 88.4%, p < 0.001; CGI-I 95.8% vs. 90.8% p < 0.05)], degree of worry,
bother and interference with daily-living activities related to OAB symptoms (p <0.05).
Conclusions: A change from tolterodine ER therapy to fesoterodine with dose escalation to 8 mg in symptomatic
OAB patients, seems to be associated with greater improvement in terms of both patient-reported-treatment
benefit and clinical global impression of change. Improvement was not affected by age.
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Overactive bladder (OAB) is a lower urinary tract dis-
order characterized by urgency with or without urge in-
continence, often with increased daytime frequency and
nocturia [1-4]. The prevalence of OAB increased with
age [5-8]. In Spain, the EPICC study showed that the
prevalence of OAB, previously estimated in adults
≥40 years of age at 21.5% [9], was 5.9% for women aged
25–64, 4.6% for men aged 50–65 and 38.5% for institu-
tionalized people over 65 [10]. The symptoms associated
with OAB can significantly affect the psychological, so-
cial, occupational, domestic, and sexual aspects of those
who suffer from it [11]. As a result, OAB has a negative
impact on the patient’s quality of life [12,13]. Despite the
significant impact of OAB on patients’ lives and the
availability of treatment options, only a small percentage
of elderly patients seek and receive treatment [9,14].
Antimuscarinic agents are the pharmacological main-
stay of OAB treatment [15]. Patients, however, often do
not respond to them appropriately, largely because of
non-compliance, but also due to lack of efficacy or in-
tolerance [16]. In these cases, the symptoms of these
patients may be improved by changing the drug [17-20]
and behavioural therapy techniques. In this way, previ-
ous randomized studies have demonstrated the superior
efficacy of fesoterodine over tolterodine [18,19,21].
Therapeutic benefit might be achieved with higher
doses. The literature supports that the efficacy of antic-
holinergics is enhanced by dose escalation [22-24].
Moreover, flexible dosing reflects clinical practice better
than fixed dosing [23]. Fesoterodine is a nonselective
antimuscarinic agent that has showed a dose-dependent
response [22]. This dose response has not been demon-
strated with all of the other antimuscarinic agents that
offer multiple doses [4].
Several studies have suggested that antimuscarinic
agents are generally effective and well-tolerated in older
subjects [25-29]. However, the use of drugs in clinical
trials markedly differs from that of the routine
clinical practice in several aspects, thus limiting the
generalization of results [30]. In this sense, non-
interventional studies, may provide complementary in-
formation on the effectiveness of specific treatments in
real clinical practice settings [31]. Then, data from open-
label or observational studies exploring the subjective
patient perception of the effectiveness of fesoterodine, in
symptomatic OAB subjects not satisfied with toltero-
dine, would also be relevant to clinical management in
the daily practice [8,32].
Here, we carried out a post-hoc analysis from the
IMPACTA study [32] to evaluate whether aging and
dose escalation to fesoterodine 8 mg compared to feso-
terodine 4 mg, were associated with higher patient-
reported treatment benefit and clinician perception ofchange, after switching from their first OAB tolterodine
ER-based therapy, in daily clinical practice.
Methods
Study design and patients
This was a post-hoc analysis of data from a retrospect-
ive, cross-sectional observational and multicenter study
(IMPACTA), aimed at determining the factors causing
treatment change in OAB patients and the resulting de-
gree of satisfaction under normal conditions [32].
Urologists and gynecologists from all over the country
were selected at random according to the geographic
population density. The original study included outpati-
ents of both genders over 18 years of age, diagnosed
with OAB, currently symptomatic in accordance with
clinical judgement (OAB-V8 score ≥8) [33]. At the phy-
sician’s discretion, treatment was changed due to any
cause within the 3–4 months prior to the visit. This
post-hoc analysis only included those patients who ful-
filled the above-mentioned selection criteria, and who
were switched to daily fesoterodine from their first tol-
terodine ER-based therapy. Fesoterodine dosage could
either be maintained at 4 mg or increased to, 8 mg. All
patients provided their informed written consent. In ac-
cordance with the Spanish recommendations, the study
was approved by the Clinical Research Ethics Committee
of Hospital General Universitario of Valencia. The study
was conducted in accordance with the principles con-
tained in the Declaration of Helsinki for studies in
humans.
Measurements and instruments
The patient-reported treatment benefit of changing was
assessed using the self-administered Treatment Benefit
Scale (TBS) [34]. The physician-reported treatment im-
provement resulting from change was assessed by the
Clinical Global Impression of Improvement (CGI-I)
scale [35]. Patients also completed ad-hoc questions
about the self-perceived treatment satisfaction/prefer-
ence, and degree of worry, bother and interference with
daily living activities due to urinary symptoms. Drug
compliance was assessed by the Morisky-Green scale
[36]. Demographic data, concomitant treatments in the
last 3 months and reasons for OAB treatment switch,
were also collected by the investigator at the single visit.
The OAB-V8 [33] is a reliable 8-item questionnaire
used to identify patients with OAB symptoms. Each item
is scored on a 6-point Likert scale ranging from 0 (not
at all) to 5 (a very great deal). Total score is obtained by
adding up the score of each item. Patients were consid-
ered to have OAB if their OAB-V8 score was ≥ 8.
The CGI [35] consists of two subscales. The first sub-
scale, severity of illness (CGI-S), assesses the clinician’s
impression of the patient’s current state of illness. It is
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The Global Improvement Subscale (CGI-I), assesses the
patient’s improvement or worsening rating 1–7 (1 = very
much improved, 2 = much improved, 3 =minimally
improved, 4 = no change, 5 = minimally worse, 6 =much
worse, 7 = very much worse).
The TBS [34] is a self-administered single-item instru-
ment, used to compare the current state of their urinary
problems with their state before the start of the study. It
is scored from 1 to 4 (1 = greatly improved, 2 = improved,
3 = no change, 4 = worsened during the treatment).
The Morinsky-Green questionnaire [36] is a four-
question survey to assess the patient’s treatment adher-
ence. Patients were classified according to the number
of questions answered correctly: compliant (4 questions),
partially compliant (3 questions) or non-compliant
(≤2 questions).
Ad-hoc patient questions were scored using a 5-point
Likert-type scale: 1 = not at all, 2 = a little, 3 = some, 4 =
quite a bit and 5 = very much/quite a lot. Subjects were
asked to rate the degree of worry, bother and impact on
their daily-life activities with regard to different OAB
symptoms, as well as their satisfaction with current
treatment. The preference for current or previous medi-
cation was assessed by patients as: I prefer the new one, I
have some preference for the new, I don’t have any pre-
ference, I prefer the previous one. Worry about urinary
symptoms included the frequency (increased frequency
of micturition during the daytime), incontinence during
sexual intercourse, nocturia, frequency of urinary tract
infections, urgency, bladder pain, urge incontinence,
urinary difficulties (in starting to urinate, resulting in
delayed bladder emptying when the subject is ready toFigure 1 Summary of study populations.urinate) and stress incontinence. The degree of bother
was assessed by urinary frequency (the patient believes
he/she urinates too often during the day), urgency (sud-
den, irresistible need to urinate without delay) and urge
incontinence (urine loss associated with a strong desire
to urinate). Finally, interviewed patients rated the inter-
ference of urinary symptoms with their everyday daily-
live such as their normal, leisure, occupational and
household activities.
Statistical methodology
Patients were distributed into groups according to doses
administered (4 mg, 8 mg) and age (<65 yr, ≥65 yr). As
used in several previous studies, [27,28,37] the age range
cut-off value to define “older” was set at ≥ 65 years old.
The patient’s degree of improvement or worsening
according to the CGI-I subscale was categorized as
improved (very much improved, much improved, min-
imally improved), no change or impaired (minimally
worse, much worse, very much worse). The current state
of the patient’s urinary problems compared with the
state before the start of the study, according to the TBS,
was also grouped into three categories: improved
(greatly improved, improved) no change or impaired
(worsened during the treatment).
A descriptive statistical analysis of all the variables was
performed, including central tendency and dispersion
measures for continuous variables, and absolute and
relative frequencies for categorical variables. Analysis of
variance, parametric and robust with Levene test of homo-
geneity was used to analyze continuous variables and the
Chi square test for qualitative variables. Pearson’s correl-
ation coefficient was calculated between ad-hoc OAB
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multivariate analysis controlling for confounding variables
(univariate general linear models and logistic regression
models) were applied. All results were adjusted for sex,
driven treatment change, treatment adherence, treatment
length and reason for switching.
The level of significance of the statistical tests was 5%
and they were bilateral. All the analyses were performed
with the SPSS statistical package, version 17 and 19.Results
Subjects
A total of 3,365 patients were included in the IMPACTA
study. 748 subjects were analyzed in this post-hoc ana-
lysis [55.9% <65 yr, 44.1% ≥65 yr; 30.2% 4 mg, 68.0%
8 mg] from those 842 that received previously toltero-
dine as a 1st therapy (Figure 1). Table 1 shows demo-
graphic and clinical characteristics of the patients.
Overall, most subjects were women (83.5%) and the
mean age was 61.5 years (Table 1). Patients were of early
diagnosis, with a mean time since diagnosis of one year.
The principal concomitant conditions, besides high
blood pressure, were diabetes mellitus, frequent urinary
tract infections and obesity. The majority of the patients
were receiving concomitant medications (67.3%). Gender
was the only characteristic statistically different between
the dose groups (p = 0.014, Table 1). However, the
age groups were not homogeneous for gender, body
mass index, and mean time since OAB diagnosis. Con-
comitant conditions, in particular high blood pressure
were also more frequent in the older group (Table 1).Table 1 Demographic and clinical characteristics of patients
Total N(748) 4 mg N(22
Gender (woman), % 83.5 83.5
Age, mean (SD), yr 61.5(11.0) 61.2(11.1)
BMI, mean (SD), Kg/m2 26.6(3.4) 26.5(3.7)
OAB evolution time, mean (SD), d. 389.7(618.6) 405.6(695.7
OAB-V8 score (0–40) 17.6(7.1) 17.4(7.4)
Concomitant conditions, % 69.8
Obesity (BMI≥ 30 Kg/m2) 12.7 14.6
HBP 45.1 45.1





Concomitant medication, % 67.3 69.8
SD Standard deviation; BMI Body Mass Index; OAB (overactive bladder); HBP High bl
groups < 0.001; §p between groups < 0.05.Fesoterodine 8 mg was prescribed to 69% of the patients
under 65 years old and to 70% of the older patients.Switching characteristics
In the majority of cases (75.2%) switching treatment
from tolterodine ER to fesoterodine was due to the
investigator’s decision (Table 2). The most common rea-
son for switching was lack of effectiveness (66.8%)
(Table 2). Between dose groups, this reason was signifi-
cantly most frequent in the higher dose group (70.9% vs.
58.0%, p < 0.05). Whereas side effects, were the cause of
the switch in 23.5% of those titrated to 4 mg and in
16.1% of those escalating to 8 mg (p < 0.05, Table 2).
When patients were evaluated in this trial, subjects
had been on treatment with fesoterodine for nearly two
months (Table 2). The treatment length was significantly
higher in the greater dose group (68.8 vs. 60.1 days;
p < 0.003) and in the older patients (69.2 vs. 63.8 days;
p < 0.042). Thirty-one percent of the patients showed
compliance with the current treatment (correct response
to 4 out of the 4 questions in the Morinsky-Green ques-
tionnaire). Compliance rate was higher with 8 mg dosing
(33.5% vs. 24.9%, p = 0.035) and similar between age
groups (Table 2).Treatment benefit of change
The illness status of the patients after the change of
treatment was mildly ill, CGI-S mean (SD) [total 3.2
(1.2); doses groups (3.2 (1.1) 4 mg vs. 3.1 (1.2) 8 mg,
p = 0.252); age groups 3.1 (1.2) <65 yr vs. 3.2 (1.1)















ood pressure; DM Diabetes mellitus; CVA Cerebrovascular Accident*p between
Table 2 Reason for and characteristics of switching
Total N(748) 4 mg N(226) 8 mg N(509) <65 yr. N(418) ≥65 yr. N(330)
Driven treatment change, %
Patient request 24.8 29.8 21.7 24.7 24.9
Investigator decision 75.2 70.2 78.3§ 75.3 75.1
Principal reason for switching, %
Lack of effectiveness 66.8 58.0 70.9§ 67.0 66.7
Side-effects 18.4 23.5 16.1 17.0 20.3
Bad compliance 6.1 8 5.3 7.2 4.8
Others 8.5 10.5 7.7 8.9 8.2
Treatment length‡, mean (SD), d. 66.2(36.2) 60.1(34.8) 68.8(36.7)§ 63.8(36.1) 69.2(36.2)§
Treatment compliance £, % 31.0 24.9 33.5§ 31.6 30.3
‡at the time of study visit; £:% of compliers (4 Morinsky-Green questions answered correctly); *:p between groups < 0.001; §:p between groups < 0.05.
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changing is showed in Figure 2. 94.4% of the overall
patients improved in the physician’s judgement as per
the CGI-I scoring after the change to fesoterodine.
94.2% of the patient rating improved on the TBS
(Figure 2). The differences between age groups were not
statistically significant (p = 0.655, Figure 2). Regarding
dose groups, the physician-reported treatment benefit
(CGI-I) was significantly higher with the 8 mg doseFigure 2 Patient and physician-reported treatment benefit after switc
Improvement subscale; TBS, Treatment Benefit Scale.(95.8% vs. 90.8%; p = 0.04). The proportion of patients
who reported being improved, according to TBS, was
also significantly higher in the fesoterodine 8 mg group
compared with 4 mg (97.1% vs. 88.4%; p < 0.001). Table 3
and 4 summarize patients urinary symptoms scoring in
relation to bother, worry and impact on daily living
items by age and dose, respectively. The symptoms that
caused most concern (somewhat/quite a bit) to the
patients as a whole were increased frequency during thehing from tolterodine ER to fesoterodine. CGI-I, Global
Table 3 Urinary symptoms improvement after switching from tolterodine ER to fesoterodine according to age of
patients
Urinary symptoms(not at all = 0 to quite a lot = 5) Total <65 years >65 years P value between groups r₤
Worry
Frequency 3.2 (3.1-3.3) 3.2 (3.1-3.3) 3.3 (3.1-3.4) 0.325 0.056
Incontinence during sexual attempt 2.2 (2.2-2.3) 2.3 (2.2-2.4) 2.0 (1.9-2.2) 0.008 −0.128‡
Nocturia 3.0 (2.9-3.1) 3.0 (2.9-3.1) 3.1 (3.0-3.3) 0.051 0.104*
Frequency of infections 2.4 (2.3-2.5) 2.4 (2.2-2.5) 2.4 (2.2-2.5) 0.923 0.022
Urgency 3.2 (3.1-3.3) 3.2 (3.1-3.3) 3.3 (3.1-3.4) 0.585 0.044
Bladder pain 2.3 (2.3-2.4) 2.3 (2.2-2.4) 2.4(2.2-2.5) 0.775 0.034
Urge incontinence 3.1 (3.0-3.3) 3.1 (2.9-3.2) 3.2 (3.1-3.3) 0.211 0.055
Urinary difficulties 2.2 (2.1-2.3) 2.1 (2.0-2.2) 2.3 (2.2-2.4) 0.070 0.141‡
Stress incontinence 2.2 (2.1-2.3) 2.1 (2.0-2.2) 2.2 (2.1-2.4) 0.266 0.028
Bother
Urinary frequency 3.2 (3.2-3.3) 3.2 (3.1-3.3) 3.3 (3.2-3.4) 0.453 0.029
Strong desire to urinate 3.3 (3.2-3.4) 3.3 (3.1-3.4) 3.3 (3.2-3.4) 0.642 0.022
Urine loss associated with a strong desire to urinate 3.1 (3.0-3.2) 3.1 (2.9-3.2) 3.2 (3.1-3.3) 0.117 0.055
Interference with daily-living activities
Usual activities 3.0 (2.9-3.1) 3.0 (2.9-3.1) 3.1 (2.9-3.2) 0.519 0.034
Leisure 3.1 (3.0-3.2) 3.1 (3.0-3.2) 3.1 (3.0-3.2) 0.761 −0.005
Work/domestic activities 2.5 (2.4-2.6) 2.7 (2.6-2.8) 2.2 (2.0-2.3) <0.001 −0.197‡
p significance level adjusted by sex, driven of treatment change, treatment adherence, treatment length, reason for switching; Values are mean (95% Confidence
Interval) ₤ Pearson coefficient of correlation between symptom score and age. *p < 0.05; ‡p ≤ 0.001.
Table 4 Urinary symptoms improvement after switching from tolterodine ER to fesoterodine according to fesoterodine
dose at the study visit
Urinary symptom(not at all = 0 to quite a lot = 5) Total 4 mg 8 mg p value between groups
Worry
Frequency 3.2 (3.1-3.3) 3.4 (3.3-3.5) 3.1 (3.0-3.2) 0.001
Incontinence during sexual attempt 2.2 (2.2-2.3) 2.1 (1.9-2.2) 2.2 (2.1-2.4) 0.075
Nocturia 3.0 (2.9-3.1) 3.2 (3.1-3.4) 3.0 (2.9-3.1) 0.010
Frequency of infections 2.4 (2.3-2.5) 2.4 (2.2-2.5) 2.4 (2.3-2.5) 0.812
Urgency 3.2 (3.1-3.3) 3.4 (3.2-3.5) 3.2 (3.1-3.3) 0.026
Bladder pain 2.3 (2.3-2.4) 2.4 (2.3-2.6) 2.3 (2.2-2.4) 0.207
Urge incontinence 3.1 (3.0-3.3) 3.3 (3.2-3.5) 3.1 (3.0-3.2) 0.008
Urinary difficulties 2.2 (2.1-2.3) 2.2 (2.0-2.3) 2.2 (2.1-2.3) 0.691
Stress incontinence 2.2 (2.1-2.3) 2.1 (1.9-2.3) 2.2 (2.1-2.3) 0.304
Bother
Urinary frequency 3.2 (3.2-3.3) 3.4 (3.3-3.6) 3.2 (3.1-3.2) 0.001
Strong desire to urinate 3.3 (3.2-3.4) 3.5 (3.4-3.7) 3.2 (3.1-3.3) <0.001
Urine loss associated with a strong desire to urinate 3.1 (3.0-3.2) 3.3 (3.1-3.5) 3.0 (2.9-3.1) 0.007
Interference with daily-living activities
Usual activities 3.0 (2.9-3.1) 3.1 (3.0-3.3) 3.0 (2.9-3.1) 0.119
Leisure 3.1 (3.0-3.2) 3.2 (3.1-3.4) 3.0 (2.9-3.1) 0.032
Work/domestic activities 2.5 (2.4-2.6) 2.5 (2.3-2.6) 2.4 (2.3-2.5) 0.717
p significance level adjusted by sex, driven of treatment change, treatment adherence, treatment length, reason for switching; Values are mean (95% Confidence
Interval).
Castro-Diaz et al. BMC Urology 2012, 12:19 Page 6 of 9
http://www.biomedcentral.com/1471-2490/12/19
Castro-Diaz et al. BMC Urology 2012, 12:19 Page 7 of 9
http://www.biomedcentral.com/1471-2490/12/19day, urgency, nocturia and urge incontinence (Table 3).
The strong desire to urinate was the symptom that
causes greatest bother. OAB symptoms interfered princi-
pally with leisure and usual activities.
Compared with younger subjects, patients ≥ 65 showed
similar results except for worry about incontinence
during sexual attempt (p = 0.008) and interference with
work/domestic activities (p < 0.001) which were signifi-
cantly higher in the younger group (Table 3).
Regarding dose groups, patients who received a dose
escalation to 8 mg, rated significantly lower their worry
and bother-related to all usual OAB symptoms as
frequency, nocturia, urgency and urge incontinence, com-
pared with 4 mg. (p < 0.05, Table 4). The interference
with daily-living activities due to OAB symptoms,
improved with higher dosing, particularly in the case of
leisure (p < 0.05, Table 4).
Overall, patients reported being satisfied (somewhat/quite
a bit) with fesoterodine treatment, with a mean score (SD)
of 3.7 (0.9). Nearly all subjects (92.8%) declared preferring/
having some preference for fesoterodine.
Younger and older patients both showed a similar
treatment satisfaction [mean (SD): 3.7 (0.9) vs. 3.6 (0.8),
p = 0.256] and preference for the new treatment (mean
(SD): 93.0% vs. 92.4%, p = 0.888).
Between dose groups, patient satisfaction with the new
treatment was greater with the higher dosing [mean
(95% CI): 3.7 (3.7-3.8) vs. 3.5 (3.4-3.6), p = 0.003]. The
proportion of patients who reported preferring/having
some preference for fesoterodine was also significantly
higher with the dose of 8 mg (94.8% vs. 88.0%; p = 0.001).
Discussion
This was a post-hoc analysis, from a non-interventional
study, involving patients who expressed dissatisfaction
with their prior and first OAB treatment with toltero-
dine ER, principally because of lack of effectiveness or
tolerability problems.
The present data, show that switching to flexible doses
of fesoterodine 4 or 8 mg, in the usual clinical practice,
provided improvements in the state of the urinary pro-
blems in a very high portion of patients, both in the phy-
sician’s and patient’s point of view. Furthermore,
patients declared being satisfied with the new treatment,
and more than 90% of them, reported preferring fesoter-
odine treatment instead of tolterodine ER. Our findings
are in consonance with those reported in an open-label
study [8] in which flexible-dose fesoterodine significantly
improved OAB symptoms and rates of treatment satis-
faction in subjects who were dissatisfied with prior tol-
terodine therapy.
One possible reason for such findings may lie in the
pharmacological profile of fesoterodine. In contrast to
tolterodine, which is metabolized in the liver viacytochrome P450 (CYP) 2D6 to produce the active
metabolite 5-hydroxymethyl tolterodine (5-HMT), hep-
atic enzymes are not involved in the conversion of feso-
terodine to 5-HMT [19,22]. Fesoterodine is extensively
and rapidly converted to 5-HMT, so no fraction of feso-
terodine is detectable in plasma after administration, un-
like tolterodine [19,22]. Moreover, there is substantial
interindividual variability in CYP2D6 metabolic activity,
while, the esterases that convert fesoterodine to 5-HMT
do not exhibit genotypic variations [8,38,39]. Thus, the
pharmacokinetic variability among individuals treated
with fesoterodine is lower [8].
Additional explanations for these findings, particularly
the high figures of effectiveness as perceived by both clini-
cians and patients, could go in two ways. In one way, previ-
ous randomized studies have demonstrated the superior
efficacy of fesoterodine over tolterodine [18,19,21]. There-
fore, it should be no surprise to see replication of such
results in routine medical practice. On the other hand,
these findings should also be interpreted in the light of the
fact that the cohort of patients included in this analysis
needed a change in its previous tolterodine-based therapy
of their OAB symptoms. Moderate improvements, as
shown in the urinary questions (see Tables 3 and 4), could
then be perceived as important benefits from the patient’s
or clinician’s perspective, because such moderate improve-
ments were observed in the urinary symptoms that best
define the OAB condition. Finally, no possible ceiling effect
in the CGI-I scale has been described yet. However, as
the TBS is a one-item scale with four possible categories of
response (greatly improved, improved, no changed and
worsened during the treatment), a ceiling effect could not
be completely ruled-out.
To date, few studies have addressed the efficacy and
tolerability of fesoterodine in elderly patients [29,40].
Here, the benefits of switching to fesoterodine do not
seem to be age-related. Thus, the percentage of younger
patients who reached treatment benefit (according to
TBS and CGI-I scales) was similar to that in older sub-
jects. No statistically significant difference was observed
regarding the degree of worry, bother or interference
with the daily-living activities due to usual urinary symp-
toms, between younger patients and those over 65 years.
Our results were compatible with those from rando-
mized studies with antimuscarinic agents for OAB,
which showed a similar efficacy irrespective of age
[27,40]. Conversely, these results differ from those
obtained in a post-hoc analysis of data from two rando-
mized fesoterodine 4 mg and 8 mg studies. There,
patients stratified according to age into three categories
(<65, ≥65- < 75, ≥75), showed greater treatment response
and improvements in the two younger groups, while, in
the ≥75 years group, improvement was only observed
with the 8 mg dose [29].
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4 mg, fesoterodine dose escalation to 8 mg provides signifi-
cant additional improvements. In the patient’s opinion,
worry, bother and interference–related OAB symptoms,
improved or showed a trend to greater improvement with
higher dosing. 8 mg of fesoterodine provides also higher
improvement in term of both patient-reported-treatment
benefit and clinical global impression of change.
In addition, compared with subjects receiving 4 mg, a
significantly greater proportion of subjects receiving
fesoterodine 8 mg, reported drug compliance preference
and satisfaction with the new treatment. Our findings,
stemming from the usual clinical practice, were in
consonance with those reported in previous randomized
studies, where the higher 8-mg dose provides additional
benefit compared with the lower dose at most end
points [22,41]. Up to now, we are unaware of the exist-
ence of non-interventional studies that addressed the
issue of efficacy of fesoterodine dose-escalation. The
only open-label, single-arm study that addressed it, did
not compare the efficacy between subjects treated with
4-mg dose throughout study and subjects who escalated
to the 8-mg dose [8].
The availability of two doses of fesoterodine allows for
individualization of patient care [8]. Dose escalation may
allow for improved outcomes in those patients who
reported good tolerability and desire greater symptom
relief [8]. In the above-mentioned open-label study, half
of the subjects opted to escalate their fesoterodine 4 mg
dose to 8 mg [8]. In the present study nearly 70% of sub-
jects received the higher fesoterodine 8 mg dose. Here,
the reasons for dose escalation were not recorded either.
However, this could be indicative of the fact that, the
percentage of patients treated with 8 mg that switched
due to lack of tolterodine effectiveness, was significantly
higher than those in the 4 mg group. While, side effects
were the cause for switching in 23.5% of those titrated
to 4 mg vs. 16.1% of those escalating to 8 mg.
The present post-hoc analysis had limitations. We did
not capture reasons why physicians/patients did or did
not opt for dose escalation. This may be important, be-
cause the reasons underlying the decision whether or
not to increase the dose, probably varied between indivi-
duals, but reflect optimization of the balance between
efficacy and tolerability [8]. Additionally, there were lim-
itations inherent in the observational design of the study.
In this study, the groups of patients were not well-
balanced. Most of the patient characteristics assessed
were different between groups. One of them is the treat-
ment length. This could be a confounding factor, but it
is not, because the mean time of treatment length was
more than two months in all our groups, and significant
fesoterodine improvements had been reported as early
as two weeks after initiation of treatment [22].In spite of the limitations of the study, it showed the
benefit that patients dissatisfied with tolterodine ER per-
ceive upon changing to fesoterodine, which is greater at
higher doses. Patient perception of OAB treatment out-
comes may be a useful indicator of benefit and might
help drive persistence on treatment, which is known to
be poor in OAB [20].
Conclusions
Our analysis suggests that a change from tolterodine
ER-based therapy to fesoterodine in symptomatic OAB
patients was associated with increased patient treatment
benefit. Improvement was not affected by age. Moreover,
fesoterodine dose escalation to 8 mg provided significant
additional improvement in terms of treatment response,
treatment satisfaction, degree of worry-related urinary
symptoms, and drug compliance.
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